While major studies have focused on IQGAP1, indicating an oncogenic role in most cancers [7,8,9], IQGAP2 has received less attention and has been described as a tumor suppressor in most cancers [10,11,12,13,14], including gastric cancer, prostate cancer, ovarian cancer, and breast cancer. Here, IQGAP2 is linked to breast carcinoma.